Asymptomatic until fracture occurs.
Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5.
Screening is based on individual risk factors, including female sex, maternal history of fragility fracture/osteoporosis, older age, low body mass index (<20-25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease.
Fall prevention is first-line therapy.
Bisphosphonates are first-line pharmacologic therapy for postmenopausal women and men.
In postmenopausal women, estrogen is considered only for those at high risk for whom nonestrogen medications are inappropriate.
Professor in Internal Medicine
Division Chief of Mineral Metabolism
Center for Mineral Metabolism and Clinical Research
UT Southwestern Medical Center at Dallas
KS declares that he has no competing interests.
University of Texas Southwestern
AVCC declares that he has no competing interests.
Dr Khashayar Sakhaee and Dr Alberto V Cabo Chan Jr. would like to gratefully acknowledge Dr Lisa Leinau, a previous contributor to this topic. LL declares that she has no competing interests.
Veterans Administration Hospital
KO declares that she has no competing interests.
Head of Division of Applied Medicine & Professor of Rheumatology
School of Medicine & Dentistry
University of Aberdeen
DMR has attended meetings sponsored by or been paid speaker fees by Amgen, Merck, Novartis, Procter & Gamble, Roche, and Servier. He has been a paid advisor to Amgen, Merck, Novartis, Procter & Gamble, Roche, Servier, and Shire Pharmaceuticals. He has undertaken research studies funded by Amgen, Merck, Novartis, Procter & Gamble, and Roche.
Use of this content is subject to our disclaimer